Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NFE2L2 | Q16236 | 1/20 | 0.66 |
| ▸ | PARP10 | Q53GL7 | 10/20 | 0.62 |
| ▸ | PARP15 | Q460N3 | 9/20 | 0.62 |
| ▸ | PARP2 | Q9UGN5 | 2/20 | 0.57 |
| ▸ | HPGD | P15428 | 2/20 | 0.48 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.47 |
| ▸ | TSHR | P16473 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2657957 | 0.98 | NFE2L2 (0.69) | NFE2L2PARP10PARP15PARP2HPGD | |
| SCHEMBL2563096 | 0.96 | PARP10 (0.62) | NFE2L2PARP10PARP15PARP2HPGD | |
| Ethane SCHEMBL7214461 | 0.94 | NFE2L2 (0.65) | NFE2L2PARP10PARP15PARP2HPGD | |
| SCHEMBL2565996 | 0.92 | PARP15 (0.59) | NFE2L2PARP10PARP15PARP2TDP1 | |
| SCHEMBL31434447 | 0.83 | PARP15 (0.56) | NFE2L2PARP10PARP15PARP2TDP1 | |
| SCHEMBL14320483 | 0.83 | PARP15 (0.47) | NFE2L2PARP10PARP15PARP2TDP1 | |
| SCHEMBL8178695 | 0.81 | PARP10 (0.57) | NFE2L2PARP10PARP15PARP2HPGD | |
| SCHEMBL14549598 | 0.81 | NFE2L2 (0.96) | NFE2L2PARP10PARP15HPGDTDP1 | |
| SCHEMBL1674238 | 0.80 | CXCR1 (0.50) | — | |
| SCHEMBL7214458 | 0.80 | PARP10 (0.56) | NFE2L2PARP10PARP15PARP2HPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2430023-B1 | AZACYCLIC SPIRODERIVATIVES AS HSL INHIBITORS | HOFFMANN LA ROCHE (CH) | 2013-12-11 | — | — | EP | disclosed |
| US-8329904-B2 | Azacyclic derivatives | HOFFMANN-LA ROCHE INC. (US) | 2012-12-11 | — | — | US | disclosed |
| EP-2430023-A1 | AZACYCLIC SPIRODERIVATIVES AS HSL INHIBITORS | F. Hoffmann-La Roche AG (CH) | 2012-03-21 | — | — | EP | disclosed |
| WO-2010130665-A1 | AZACYCLIC SPIRODERIVATIVES AS HSL INHIBITORS | F. HOFFMANN-LA ROCHE AG (CH) | 2010-11-18 | — | — | WO | disclosed |
| US-20100292212-A1 | NEW AZACYCLIC DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2010-11-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100292212-A1 | NEW AZACYCLIC DERIVATIVES | GPR119, LDLR, LPL | NFE2L2 1257/4885PARP10 2180/4885PARP15 1789/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.